Get the Stockscreener App
3.83
5.43%
-0.22
Briacell Therapeutics Corp stock is traded at $3.83, with a volume of 122.72K.
It is down -5.43% in the last 24 hours and down -42.88% over the past month.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
See More
Previous Close:
$4.05
Open:
$4.08
24h Volume:
122.72K
Relative Volume:
0.37
Market Cap:
$15.02M
Revenue:
-
Net Income/Loss:
$-16.60M
P/E Ratio:
-4.3034
EPS:
-0.89
Net Cash Flow:
$-23.48M
1W Performance:
-23.71%
1M Performance:
-42.88%
6M Performance:
-57.44%
1Y Performance:
-93.51%
1-Day Range:
$3.8101
$4.095
1-Week Range:
$3.8101
$7.87
52-Week Range:
$3.8101
$60.45
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Name
Briacell Therapeutics Corp
Sector
Industry
Phone
(604) 921-1810
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Compare BCTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
3.85 | 15.02M | 0 | -16.60M | -23.48M | -0.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.00 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.08 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.80 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.24 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.91 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-22 | Initiated | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Stock (BCTX) Latest News
BriaCell Announces Positive Shareholder Meeting Results - MSN
HC Wainwright Has Bullish Forecast for TSE:BCT Q2 Earnings - Defense World
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting - GlobeNewswire
BriaCell's Board Secures Massive 88% Shareholder Approval at Annual Meeting - StockTitan
BriaCell Therapeutics Secures $3.05 Million in Public Offering - TipRanks
Briacell Therapeutics Announces Closing Of Public Offering -February 05, 2025 at 04:19 pm EST - Marketscreener.com
BriaCell Therapeutics Announces Closing of Public Offering - The Manila Times
BriaCell Therapeutics Announces Closing of Public Offering - Benzinga
Cancer Immunotherapy Pioneer BriaCell Secures Critical $3.05M Funding to Advance Treatment Development - StockTitan
BriaCell Therapeutics stock rises on positive clinical trial results - MSN
HC Wainwright Has Positive Estimate for TSE:BCT Q2 Earnings - MarketBeat
United Therapeutics president sells $3.5m in stock - MSN
BriaCell Stock Climbs After ‘Unprecedented’ Immunotherapy Response In Breast Cancer Patient, Retail Exudes Optimism - MSN
H.C. Wainwright raises Briacell stock target to $32 on trial success - Investing.com
BriaCell announces public offering of common shares - MSN
BriaCell Therapeutics (NASDAQ:BCTX) Given New $32.00 Price Target at HC Wainwright - Defense World
BriaCell announces public offering of common shares By Investing.com - Investing.com South Africa
BriaCell Therapeutics slumps 20%, prices $3M stock offering - MSN
BriaCell Therapeutics Announces $3.05 Million Public Offering - TipRanks
Briacell Therapeutics Prices Public Offering Of 762,500 Shares At $4 Each -February 03, 2025 at 08:04 pm EST - Marketscreener.com
BriaCell's $3.05M Capital Raise: Strategic Move or Dilution Concern? - StockTitan
Wavelo Secures Four-Year Contract Renewal with EchoStar - The Globe and Mail
BriaCell Therapeutics Announces Pricing of Public Offering - Yahoo Finance
Briacell Therapeutics Announces Proposed Public Offering Of Common Shares -February 03, 2025 at 05:36 pm EST - Marketscreener.com
BriaCell Therapeutics Shares Hit Record Low After Public Offering News - MarketWatch
BriaCell Therapeutics Announces Public Offering to Fuel Growth - TipRanks
BriaCell Therapeutics Corp (BCTX) Stock: Navigating Drops and Gains - The InvestChronicle
BriaCell Therapeutics Announces Proposed Public Offering of Common Shares - GlobeNewswire
Cancer Immunotherapy Pioneer BriaCell Launches Strategic Funding Round for Next-Gen Treatments - StockTitan
Will BriaCell Therapeutics Corp (BCTX) meet earnings estimates this quarter? - US Post News
BriaCell Stock Climbs After ‘Unprecedented’ Immunotherapy Response In Breast Cancer Patient, Retail Exudes Opt - Asianet Newsable
Promising Results and Strategic Expansion Underpin Buy Rating for BriaCell Therapeutics - TipRanks
BriaCell immunotherapy destroys metastatic breast cancer tumor | 2025-02-03 | Investing News - Stockhouse Publishing
BriaCell’s Bria-OTS™ Shows Promising Results in Resolving Breast Cancer Lung Metastasis - TipRanks
BriaCell announces resolution of lung metastasis in patient receiving Bria-OTS - TipRanks
BriaCell Therapeutics stock rises on positive clinical trial results By Investing.com - Investing.com UK
BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™ - Markets Insider
BriaCell Therapeutics (BCTX) Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS - StreetInsider.com
Breakthrough in Breast Cancer Treatment: Patient's Lung Metastasis Vanishes After Novel Immunotherapy - StockTitan
Sirius XM Earnings: What To Look For From SIRI - The Globe and Mail
1-800-FLOWERS (FLWS) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
BriaCell Therapeutics (OTCMKTS:BCTXF) Shares Down 2.3% – Here’s What Happened - Defense World
BriaCell Announces Completion of 15:1 Share Consolidation - GlobeNewswire
BriaCell Completes 15:1 Share Consolidation for Nasdaq Compliance - TipRanks
BriaCell's Major Stock Transformation: 44M Shares Become 2.9M in Critical Nasdaq Move - StockTitan
BriaCell Therapeutics (NASDAQ:BCTXW) Shares Down 11.4% – Here’s Why - Defense World
5 AI Stocks to Load Up On in 2025 - The Globe and Mail
Why Truist Analysts Think Nvidia Stock Can Gain Another 50% in 2025 - The Globe and Mail
BriaCell Therapeutics (NASDAQ:BCTX) Shares to Reverse Split on Wednesday, January 29th - Defense World
Certain Options of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 10-JAN-2025. - Marketscreener.com
BriaCell Therapeutics (CVE:BCT) Stock Price Down 3.8% – Here’s Why - Defense World
Briacell Therapeutics Corp Stock (BCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):